USMLE Step 3 Quiz: Chronic Lung Disease Management

What this quiz covers

This quiz focuses on Chronic Lung Disease Management, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 3.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Provide smoking cessation counseling and offer pharmacotherapy support (correct answer)
2. Recommend doubling ALBUTEROL use daily to prevent attacks
3. Advise stopping all inhalers to “reset” airway sensitivity
4. Encourage limiting vaccinations to avoid immune stimulation

Explanation: This question tests chronic lung disease management skills, particularly the application of clinical guidelines in decision-making for smoking cessation in COPD. Chronic lung disease management involves assessing symptom severity, optimizing treatment regimens, and coordinating care. Key principles include recognizing exacerbations, adjusting medications appropriately, and planning follow-ups. In this vignette, the patient's ongoing smoking and exacerbations indicate a key modifiable risk. The correct choice, 'Provide smoking cessation counseling and offer pharmacotherapy support', aligns with current guidelines for managing COPD by reducing progression and exacerbations. The distractor 'Recommend doubling ALBUTEROL use daily to prevent attacks' is incorrect as it does not address the root cause, a common oversight in symptom management. Teaching strategies include reinforcing the importance of guideline-based therapy and the recognition of symptom patterns. Encourage students to differentiate between acute and chronic management needs and to prioritize interventions that modify disease progression.

Question 2

1. Use peak flow zones to guide step-up therapy and seek urgent care if in red zone (correct answer)
2. Ignore peak flows and adjust medications only at annual visits
3. Stop controller inhaler when symptoms worsen to prevent tolerance
4. Use antibiotics whenever peak flow decreases below baseline

Explanation: This question tests chronic lung disease management skills, particularly the application of clinical guidelines in decision-making for asthma action plans. Chronic lung disease management involves assessing symptom severity, optimizing treatment regimens, and coordinating care. Key principles include recognizing exacerbations, adjusting medications appropriately, and planning follow-ups. In this vignette, the patient's peak flow drops and triggers indicate a need for self-management education. The correct choice, 'Use peak flow zones to guide step-up therapy and seek urgent care if in red zone', aligns with current guidelines for managing asthma by empowering patient response. The distractor 'Ignore peak flows and adjust medications only at annual visits' is incorrect as it delays intervention, a common oversight in monitoring. Teaching strategies include reinforcing the importance of guideline-based therapy and the recognition of symptom patterns. Encourage students to differentiate between acute and chronic management needs and to prioritize interventions that modify disease progression.

Question 3

1. Initiation of antifibrotic therapy with nintedanib.
2. Treatment with a long-acting bronchodilator.
3. A trial of high-dose oral corticosteroids.
4. Aggressive smoking cessation counseling and therapy. (correct answer)

Explanation: When you encounter a patient with combined pulmonary fibrosis and emphysema (CPFE), remember that addressing modifiable risk factors takes priority over symptomatic treatments. This case presents the classic CPFE pattern: upper lobe emphysema with lower lobe fibrosis in a heavy smoker, plus the characteristic severely reduced DLCO that's disproportionate to the mild airflow obstruction. Answer D is correct because smoking cessation is the single most important intervention for CPFE patients. Continued smoking accelerates both emphysematous destruction and fibrotic progression, making it the primary modifiable factor. The 35-pack-year history indicates significant ongoing exposure that must be addressed immediately to prevent further lung damage. Answer A is premature - while nintedanib may slow fibrotic progression, initiating antifibrotic therapy without first addressing the primary cause (smoking) is less effective and not the initial priority. Answer B misses the point - though bronchodilators help with airflow obstruction, they don't address the underlying disease progression. The FEV1/FVC of 0.65 shows only moderate obstruction, making this less urgent than smoking cessation. Answer C is inappropriate - high-dose corticosteroids are generally contraindicated in CPFE as they may worsen the emphysematous component and don't improve outcomes in established pulmonary fibrosis. Study tip: In CPFE cases on Step 3, always prioritize smoking cessation over symptomatic treatments. Look for the combination of upper lobe emphysema, lower lobe fibrosis, and disproportionately reduced DLCO - this pattern signals that addressing smoking takes precedence over specific therapies.

Question 4

1. A combination inhaled corticosteroid and long-acting beta-agonist (ICS/LABA). (correct answer)
2. A long-acting beta-agonist (LABA) monotherapy.
3. A long-acting muscarinic antagonist (LAMA) monotherapy.
4. A combination long-acting beta-agonist and long-acting muscarinic antagonist (LABA/LAMA).

Explanation: When you encounter a patient with features of both asthma and COPD, you're dealing with asthma-COPD overlap (ACO), which requires specific therapeutic considerations. This patient shows classic ACO features: significant smoking history (COPD risk), childhood allergies and reversible airflow obstruction (asthma features), plus elevated eosinophils suggesting type-2 inflammation. The key principle in ACO management is that these patients have underlying airway inflammation that requires anti-inflammatory treatment, unlike pure COPD where bronchodilators alone may suffice initially. The significant bronchodilator response (15% and 300 mL improvement) and eosinophilia (>300 cells/µL) strongly indicate a need for inhaled corticosteroids. Choice A is correct because ICS/LABA combination therapy addresses both the inflammatory component (ICS) and provides bronchodilation (LABA). Current guidelines recommend ICS-containing regimens as first-line therapy for ACO patients, particularly those with eosinophilia. Choice B (LABA monotherapy) is inappropriate and potentially dangerous, as LABA without ICS can increase mortality risk in asthma patients. Choice C (LAMA alone) provides bronchodilation but ignores the significant inflammatory component evidenced by the eosinophilia and reversibility. Choice D (LABA/LAMA) offers dual bronchodilation but lacks anti-inflammatory therapy, missing the key pathophysiologic driver in this patient. Remember: ACO patients always need anti-inflammatory therapy upfront. When you see reversible airflow obstruction plus eosinophilia in a patient with smoking history, think ICS-containing combinations, not bronchodilator monotherapy.

Question 5

1. Initiate long-term azithromycin therapy.
2. Refer for lung volume reduction surgery evaluation.
3. Add roflumilast to his current regimen. (correct answer)
4. Prescribe a standing order for oral corticosteroids at home.

Explanation: This patient has severe COPD with a chronic bronchitis phenotype (daily productive cough) and continues to have frequent exacerbations despite optimal triple therapy (ICS/LAMA/LABA). According to GOLD guidelines, for patients with an FEV1 < 50% and chronic bronchitis, adding roflumilast, a phosphodiesterase-4 inhibitor, is recommended to reduce exacerbations. His eosinophil count is < 300 cells/µL, making ICS benefit less certain, but he is already on it. Roflumilast is the most appropriate next step for his specific phenotype.

Question 6

1. Discontinue the ICS/LABA and switch to an as-needed albuterol inhaler only.
2. Decrease the ICS/LABA to a low-dose formulation. (correct answer)
3. Switch from the combination ICS/LABA to a medium-dose ICS inhaler alone.
4. Continue the current regimen and re-evaluate in one year.

Explanation: According to asthma management guidelines (e.g., GINA), when a patient's asthma has been well-controlled for at least 3 months, step-down therapy should be considered to find the minimum effective dose to maintain control and reduce long-term side effects. The most appropriate step-down for a patient on a medium-dose ICS/LABA is to reduce it to a low-dose ICS/LABA. Discontinuing the controller medication entirely is inappropriate, and switching to ICS alone removes the LABA that may be contributing to control. Continuing the current dose without attempting a step-down is not optimal.

Question 7

1. Long-term daily oral azithromycin.
2. Cyclical inhaled tobramycin. (correct answer)
3. Prophylactic rotating oral antibiotics (e.g., doxycycline, ciprofloxacin).
4. Daily inhaled hypertonic saline.

Explanation: For patients with non-CF bronchiectasis and frequent exacerbations (≥3 per year) who are chronically colonized with Pseudomonas aeruginosa, guidelines recommend long-term therapy with an inhaled antibiotic such as tobramycin or colistin, often in 28-day on/off cycles. This has been shown to reduce exacerbation frequency and improve quality of life. Long-term macrolide therapy (azithromycin) is an option for patients without Pseudomonas colonization or those who cannot tolerate inhaled antibiotics. Rotating oral antibiotics have a limited evidence base, and while hypertonic saline can aid mucus clearance, inhaled antibiotics are the specific intervention for suppressing chronic infection and reducing exacerbations in this context.

Question 8

1. PaO2 62 mm Hg, SaO2 91%
2. PaO2 58 mm Hg, SaO2 89%, with evidence of cor pulmonale
3. PaO2 54 mm Hg, SaO2 87% (correct answer)
4. PaO2 65 mm Hg, with oxygen desaturation to 88% during a 6-minute walk test

Explanation: The criteria for continuous long-term oxygen therapy in stable COPD patients include a resting partial pressure of arterial oxygen (PaO2) ≤ 55 mm Hg or an arterial oxygen saturation (SaO2) ≤ 88%. A PaO2 of 54 mm Hg (and SaO2 of 87%) meets this criterion. A PaO2 between 56 and 59 mm Hg or an SaO2 of 89% only qualifies a patient if there is evidence of end-organ damage, such as cor pulmonale (pulmonary hypertension, peripheral edema) or erythrocytosis (hematocrit > 55%). Oxygen desaturation only during exercise qualifies a patient for ambulatory oxygen, not continuous therapy.

Question 9

1. Initiation of a prostacyclin analog such as epoprostenol.
2. Treatment with a phosphodiesterase-5 inhibitor like sildenafil.
3. Optimization of management for his underlying lung disease. (correct answer)
4. Referral for pulmonary thromboendarterectomy.

Explanation: This patient has WHO Group 3 pulmonary hypertension, which is PH due to chronic lung disease and/or hypoxia. The cornerstone of management for this group is to treat and optimize the underlying lung disease and correct hypoxemia with supplemental oxygen. While targeted pulmonary arterial hypertension (PAH) therapies like prostacyclin analogs or PDE-5 inhibitors are used in Group 1 PAH, their use in Group 3 is controversial and not first-line, as they can worsen ventilation-perfusion mismatch. Pulmonary thromboendarterectomy is the treatment for Group 4 PH (CTEPH), not Group 3.

Question 10

1. Admit to the hospital for intravenous antibiotics.
2. Prescribe a 14-day course of oral ciprofloxacin.
3. Prescribe a 14-day course of oral trimethoprim-sulfamethoxazole. (correct answer)
4. Increase the frequency of his airway clearance therapy and observe.

Explanation: This patient is having a mild CF pulmonary exacerbation, indicated by increased symptoms and a drop in FEV1 of less than 10% from baseline. For mild exacerbations in patients who can be managed as outpatients, oral antibiotics are appropriate. The choice of antibiotic should be guided by previous sputum cultures. Since his last culture grew Staphylococcus aureus, an antibiotic with activity against it, such as trimethoprim-sulfamethoxazole, is a suitable choice. Ciprofloxacin is primarily used for Pseudomonas coverage. Hospitalization for IV antibiotics is reserved for more severe exacerbations. Observation alone is insufficient given the objective decline in lung function.

Question 11

1. Complete removal from the workplace environment. (correct answer)
2. Begin a trial of omalizumab for allergic asthma.
3. Add a leukotriene receptor antagonist such as montelukast.
4. Increase her ICS/LABA inhaler to a high-dose formulation.

Explanation: This patient's history is classic for occupational asthma, with symptoms clearly linked to her work environment. While optimizing medical therapy is important for symptom control, the definitive and most crucial long-term management strategy for occupational asthma is the complete cessation of exposure to the sensitizing agent. Continued exposure, even with medical treatment, is associated with a worse prognosis and irreversible decline in lung function. Referral to an occupational medicine specialist and discussion about workplace modification or change in employment is paramount. The other options represent medical management steps but do not address the underlying trigger.

Question 12

1. Continue low-dose maintenance prednisone indefinitely.
2. Initiate treatment with an antifibrotic agent like pirfenidone.
3. Monitor clinically with spirometry every 6-12 months. (correct answer)
4. Begin prophylactic azithromycin to prevent infectious complications.

Explanation: The cornerstone of management for hypersensitivity pneumonitis (HP) is antigen avoidance. This patient has successfully removed the inciting antigen and has had a complete clinical, functional, and radiographic response to a course of corticosteroids. Since he is now stable and off steroids, the most appropriate long-term management is periodic monitoring with clinical evaluation and pulmonary function testing (spirometry) to ensure his disease remains quiescent. There is no role for indefinite maintenance prednisone in a stable patient, nor for antifibrotic agents in non-progressive, non-fibrotic HP. Prophylactic antibiotics are not indicated.

Question 13

1. Adding daily theophylline to his medication regimen.
2. Providing a prescription for home oxygen therapy.
3. Referring him to a comprehensive pulmonary rehabilitation program. (correct answer)
4. Prescribing a long-term, low-dose oral corticosteroid.

Explanation: Pulmonary rehabilitation is a comprehensive intervention for patients with chronic respiratory diseases that includes exercise training, education, and psychosocial support. For patients with COPD, initiating pulmonary rehabilitation after a recent hospitalization for an exacerbation has been shown to significantly reduce hospital readmissions and improve quality of life and exercise tolerance. Theophylline and long-term oral corticosteroids have unfavorable risk-benefit profiles and are not first-line choices. Home oxygen is only indicated if the patient meets specific hypoxemia criteria, which are not mentioned.

Question 14

1. Continue with as-needed albuterol only, as ICS is contraindicated in pregnancy.
2. Reinstate her previous medium-dose inhaled corticosteroid immediately. (correct answer)
3. Initiate montelukast as a safer alternative to an inhaled corticosteroid.
4. Prescribe a short course of oral prednisone to regain control.

Explanation: Poorly controlled asthma poses a greater risk to the mother and fetus (e.g., pre-eclampsia, low birth weight, preterm birth) than the medications used to treat it. Inhaled corticosteroids, particularly budesonide, are considered safe and are the preferred controller therapy during pregnancy. The most appropriate step is to reinstate her effective pre-pregnancy medication to regain asthma control. Continuing with albuterol alone is inadequate and risky. Montelukast is a second-line agent. A short course of oral steroids might be needed for a severe exacerbation, but the priority here is re-establishing maintenance controller therapy.

Question 15

1. Initiate therapy with an endothelin receptor antagonist like bosentan.
2. Add an inhaled prostacyclin to his current regimen.
3. Switch from warfarin to a direct oral anticoagulant.
4. Refer to a specialized center for pulmonary thromboendarterectomy evaluation. (correct answer)

Explanation: When you encounter a patient with recurrent thromboembolism and persistent pulmonary hypertension despite anticoagulation, consider chronic thromboembolic pulmonary hypertension (CTEPH). This condition develops when organized thrombi obstruct pulmonary arteries, creating fixed vascular resistance. This patient's presentation is classic for CTEPH: recurrent unprovoked DVT/PE, progressive dyspnea after initial treatment, multiple mismatched V/Q defects (indicating organized clots), and confirmed pre-capillary pulmonary hypertension. The key distinguishing feature is that perfusion defects persist despite adequate anticoagulation, unlike acute PE where defects typically resolve. Pulmonary thromboendarterectomy (PTE) is the gold standard treatment for CTEPH, offering potential cure by surgically removing organized thromboembolic material. However, not all patients are surgical candidates, requiring specialized evaluation at expert centers to assess operability based on clot location, patient comorbidities, and technical feasibility. Option A (bosentan) and B (inhaled prostacyclin) are pulmonary arterial hypertension (PAH) medications. While they may provide symptomatic relief in inoperable CTEPH, they're second-line treatments and shouldn't be initiated before surgical evaluation, as PTE offers superior outcomes. Option C (switching anticoagulants) addresses anticoagulation but doesn't treat the underlying organized clots causing pulmonary hypertension. The patient needs definitive intervention beyond anticoagulation alone. Remember: CTEPH is the only potentially curable form of pulmonary hypertension. Always consider surgical evaluation first in patients with this diagnosis, as medical therapy alone leaves the underlying pathology untreated.

Question 16

1. Prednisone
2. Bosentan
3. Nintedanib
4. Sirolimus (correct answer)

Explanation: When encountering a patient with lymphangioleiomyomatosis (LAM), you need to understand this rare multisystem disease that primarily affects women of childbearing age. LAM involves abnormal proliferation of smooth muscle-like cells (LAM cells) that leads to airway obstruction, cystic destruction of lung tissue, and progressive respiratory failure. The key is recognizing that LAM is driven by mutations in the TSC1/TSC2 genes, which normally regulate the mTOR (mechanistic target of rapamycin) pathway. Sirolimus (D) is correct because it's an mTOR inhibitor that directly targets the underlying pathophysiology of LAM. Clinical trials have demonstrated that sirolimus can stabilize lung function, reduce lymphangioleiomyoma size, and improve quality of life in LAM patients. It works by inhibiting the hyperactive mTOR signaling that drives LAM cell proliferation and angiomyolipoma growth. Prednisone (A) is contraindicated in LAM because corticosteroids can accelerate lung function decline and worsen the disease progression. This is a critical point that distinguishes LAM from other cystic lung diseases. Bosentan (B) is an endothelin receptor antagonist used primarily for pulmonary arterial hypertension, not for the underlying cystic lung destruction seen in LAM. Nintedanib (C) is a tyrosine kinase inhibitor used for idiopathic pulmonary fibrosis, but it doesn't address the mTOR pathway dysregulation central to LAM pathogenesis. Remember: LAM is an mTOR-driven disease, so treatment focuses on mTOR inhibition with sirolimus. Never use steroids in LAM patients, as they worsen outcomes.

Question 17

1. Observe with serial pulmonary function tests and chest x-rays. (correct answer)
2. Start methotrexate as a steroid-sparing agent.
3. Initiate treatment with oral prednisone.
4. Prescribe a long-acting bronchodilator.

Explanation: When you encounter sarcoidosis questions on Step 3, remember that management depends entirely on whether the patient has symptoms or organ dysfunction. This case presents classic Stage II pulmonary sarcoidosis in an asymptomatic patient. The correct approach here is observation with serial monitoring (Answer A). This patient has bilateral hilar lymphadenopathy with parenchymal involvement (micronodules) but crucially has normal pulmonary function tests and no symptoms. In asymptomatic sarcoidosis patients with preserved organ function, the standard of care is watchful waiting with regular chest imaging and pulmonary function monitoring, as many cases resolve spontaneously. Answer C (oral prednisone) is incorrect because corticosteroids are reserved for symptomatic patients or those with evidence of organ dysfunction. Starting steroids in asymptomatic patients exposes them to unnecessary side effects without clear benefit. Answer B (methotrexate) is wrong because this steroid-sparing agent is only considered after steroids have been initiated and proven necessary - it's not first-line therapy. Answer D (bronchodilator) is incorrect because this patient has restrictive lung disease from granulomatous inflammation, not obstructive disease, and her pulmonary function tests are normal anyway. The key teaching point: In sarcoidosis, "asymptomatic with normal organ function" equals observation, regardless of radiographic findings. Only treat when patients develop symptoms (dyspnea, fatigue, organ-specific symptoms) or objective evidence of organ impairment (abnormal PFTs, hypercalcemia, cardiac involvement, etc.). Don't be distracted by elevated ACE levels or impressive imaging - treat the patient, not the test results.

Question 18

1. Initiation of an inhaled corticosteroid.
2. Referral for lung transplantation evaluation.
3. Addition of long-term oral prednisone.
4. Intravenous alpha-1 proteinase inhibitor augmentation therapy. (correct answer)

Explanation: This patient has alpha-1 antitrypsin deficiency (AATD), a genetic cause of COPD. Intravenous augmentation therapy with pooled human alpha-1 proteinase inhibitor is indicated for patients with AATD and evidence of emphysema with an FEV1 between 30% and 65% of predicted. This therapy aims to slow the progression of emphysema. His FEV1 of 55% falls within this range. Inhaled corticosteroids are not routinely recommended in AATD unless there is concomitant asthma or frequent exacerbations. Referral for lung transplantation is premature at this FEV1 level. Long-term oral steroids are not indicated and have significant side effects.

Question 19

1. Initiate broad-spectrum antibiotics and supportive care.
2. Administer high-dose systemic corticosteroids. (correct answer)
3. Increase the dose of nintedanib.
4. Begin treatment with diuretics for suspected heart failure.

Explanation: This patient's presentation is highly suggestive of an acute exacerbation of IPF, defined as an acute, clinically significant respiratory deterioration of unidentifiable cause. After excluding other causes like infection (negative cultures) and heart failure (unchanged echo), the standard of care for a suspected acute exacerbation of IPF is treatment with high-dose systemic corticosteroids (e.g., pulse-dose methylprednisolone). While supportive care and ruling out infection are crucial, corticosteroids are the primary treatment for the underlying inflammatory process of the exacerbation. Antifibrotic therapy (nintedanib) is not adjusted during an acute exacerbation, and there is no evidence for diuretics.

Question 20

1. Increase the dose of her long-acting morphine.
2. Refer her for a formal palliative care consultation. (correct answer)
3. Prescribe a short-acting benzodiazepine for anxiety.
4. Reassure her that her current regimen is sufficient to manage symptoms.

Explanation: This patient with advanced IPF is expressing existential distress and fears related to the end of life, which go beyond simple symptom management. The most appropriate step is to involve a specialized palliative care team. Palliative care focuses on improving quality of life by addressing physical, psychosocial, and spiritual suffering. A formal consultation can facilitate in-depth goals-of-care discussions, advance care planning, and provide expert management of complex symptoms and emotional distress. While adjusting medications might be part of the plan, the immediate need is for a comprehensive, interdisciplinary approach that a palliative care team can provide.